{"id":"risedronate-combine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Abdominal pain"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Back pain"}]},"_chembl":{"chemblId":"CHEMBL1654","moleculeType":"Small molecule","molecularWeight":"305.10"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Risedronate is a bisphosphonate that binds to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This results in increased bone density and reduced risk of fractures.","oneSentence":"Risedronate combines with other medications to inhibit bone resorption by acting on osteoclasts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:16.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoporosis in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT01806792","phase":"PHASE3","title":"Post-menopausal Women Osteoporosis(Phase III)","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2009-11","conditions":"Postmenopausal Women Osteoporosis","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- Other name : Risenex M(risedronate 150mg and cholecalciferol 30,000 IU combined)"],"phase":"phase_3","status":"active","brandName":"risedronate combine","genericName":"risedronate combine","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risedronate is a small molecule inhibitor of farnesyl diphosphate synthase, classified as an INHIBITOR. It is used to treat postmenopausal women with osteoporosis, as indicated by clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}